P891: Ixazomib, Pomalidomide and Dexamethasone (Ixpd) in Relapsed or Refractory Multiple Myeloma (Rrmm) Characterized With High-Risk Cytogenetics. Ifm 2014-01

Bobin, Arthur; Manier, Salomon; Keizer, Jean; Karlin, L.; Perrot, A.; Hulin, Cyrille; Caillot, Denis; Mariette, Clara; Lenain, Pascal; Richez, V.; Tiab, M.; Touzeau, Cyrille; Jaccard, Arnaud; Decaux, O.; Araujo, Carla; Belhadj, K.; Benboubker, Lotfi; Deal, Cécile; Macro, M.; Vincent, Laure; Arnulf, Bertrand; Bareau, Benoit; Braun, Thorsten; Calmettes, C.; mamoun, D.; Zerazhi, Hacène; Demarquette, H.; Feugier, Patrick; Fohrer-sonntag, C.; Petillon, Marie-Odile; Avet‐Loiseau, Hervé; Leleu, Xavier

doi:10.1097/01.hs9.0000846440.48761.8d

HemaSphere

2022

DOI: 10.1097/01.hs9.0000846440.48761.8d

|View full text |Cite

P891: Ixazomib, Pomalidomide and Dexamethasone (Ixpd) in Relapsed or Refractory Multiple Myeloma (Rrmm) Characterized With High-Risk Cytogenetics. Ifm 2014-01

Arthur Bobin

Salomon Manier

Jean Keizer

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

Hartley‐Brown,

Weisel,

Bitetti

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

SummaryThe growing use of frontline lenalidomide treatment in multiple myeloma (MM) is increasing the proportion of lenalidomide‐refractory patients, which may limit the efficacy of subsequent lines of treatment (LOT). This systematic literature review (January 2008–October 2023) of clinical trials (CT) and real‐world studies (RW) assessed treatment outcomes in adults with relapsed/refractory MM (RRMM) who were previously treated with ≥1 LOT, progressed and were lenalidomide‐refractory. Medline, EMBASE and additional electronic databases were searched for articles published in English. Primary outcomes included progression‐free survival (PFS), overall survival (OS) and overall/objective response rate (ORR); 24 CT and 19 RW were included. For CT, the population‐weighted mean of median PFS (CT = 14) and OS (CT = 6) were shorter in the lenalidomide‐refractory cohort (months: 8.8 [n = 2699] and 21.7 [n = 1066], respectively) than the intent‐to‐treat population (months: 13.8 [n = 5380] and 35.9 [n = 2264], respectively); the population‐weighted (N = 2142) mean ORR for lenalidomide‐refractory patients (CT = 18) was 56.0%. RW reported considerable variation in PFS (RW = 7), OS (RW = 8) and ORR (RW = 8); and median PFS (RW = 2; months) was lower in lenalidomide/bortezomib‐refractory (5.5/5.5; n = 81/n = 25) versus lenalidomide‐refractory (7.3/8.0; n = 81/n = 61) patients. These data provide evidence that clinical trials and real‐world outcomes are suboptimal in lenalidomide‐refractory patients with RRMM, highlighting the need to improve treatment options for this population.

show abstract

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

Hartley‐Brown,

Weisel,

Bitetti

et al. 2024

Br J Haematol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

P891: Ixazomib, Pomalidomide and Dexamethasone (Ixpd) in Relapsed or Refractory Multiple Myeloma (Rrmm) Characterized With High-Risk Cytogenetics. Ifm 2014-01

Cited by 1 publication

References 0 publications

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

Multiple myeloma refractory to lenalidomide: A systematic literature review of trials and real‐world evidence

Contact Info

Product

Resources

About